Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche's Hemlibra Priced And Labeled To Beat Competition, Safety Concern

Executive Summary

Genentech/Roche's Hemlibra, now FDA-approved for hemophilia A patients with inhibitors, offers a once-weekly injection, impressive efficacy with a safety concern that appears to be manageable, and a price that's at least half the cost of the established prophylaxis regimen.

You may also be interested in...



Novo Nordisk Halts Phase III Concizumab Hemophilia Trials After Three Thrombotic Events

No new patients will be enrolled, and trial participants will stop treatment with the tissue factor pathway inhibitor antibody, a class with four prior suspended hemophilia programs.

Eyes On Chugai's Hemlibra Supply Price As Sales Grow

Set against what were seen as solid third quarter results, analysts are keeping an eye on planned changes to Chugai's supply price of Hemlibra to global licensee Roche.

Hemophilia Seen As Good Testing Ground For Commercializing Gene Therapy

With a well characterized genetic driver, a clear marker to show whether it's working, and available treatments that carry high annual costs, hemophilia may be a good testing ground for commercializing gene therapy, but payers still have to work out how to reimburse the one-time medicines.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID052006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel